Christos S Karapetis
Affiliation: Flinders University
- Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow upC S Karapetis
Department of Medical Oncology, Guy s Hospital, London, United Kingdom
Intern Med J 33:427-35. 2003..The objective of the present study was to evaluate the use of FDG-PET in the setting of advanced GCT, and to determine the influence of FDG-PET on subsequent patient management...
- PET and PLAP in suspected testicular cancer relapse: beware sarcoidosisC S Karapetis
Department of Medical Oncology, Guy's Hospital, London, UK
Ann Oncol 12:1485-8. 2001..Sarcoidosis, a condition that has been associated with testicular cancer, should always be considered in the differential diagnosis...
- K-ras mutations and benefit from cetuximab in advanced colorectal cancerChristos S Karapetis
Flinders Medical Centre and Flinders University, Adelaide, Australia
N Engl J Med 359:1757-65. 2008..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
- A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomasChristos S Karapetis
Department of Medical Oncology, Guy s Hospital, London, UK
Asia Pac J Clin Oncol 6:298-305. 2010..Epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) is a well-established chemotherapy regimen but a continuous chemotherapy infusion is not always feasible or acceptable...
- A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal CancerRajiv Kumar
Department of Medical Oncology, Flinders Medical Center, Bedford Park, South Australia 5042, Australia
Cancer 119:722-8. 2013..Life expectancy is increasing, and more patients are presenting with cancer at an advanced age (≥80 years). Optimal management for this group of patients has not been well defined...
- Current opinion on optimal treatment for colorectal cancerTimothy J Price
The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, South Australia, Australia
Expert Rev Anticancer Ther 13:597-611. 2013..This article reviews the evidence in support of modern treatments for CRC and the decision-making behind the treatment choices, their benefits and toxicities...
- Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factorsStephen J Clarke
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
Crit Rev Oncol Hematol 85:121-35. 2013..In this article, the current concepts of tumour and patient-related predictive factors in CRC management are reviewed...
- Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancerMuhammad A Khattak
Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia
Clin Colorectal Cancer 11:247-54. 2012..Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease...
- Cetuximab for the treatment of colorectal cancerDerek J Jonker
Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
N Engl J Med 357:2040-8. 2007..Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR...